Inhibition of HIV Infection in Highly Susceptible Cells with Human beta-Defensins - Induction of APOBEC3G Via Chemokine Receptors

Mark K. Lafferty,Jennifer Bharucha,Olga Latinovic,Lingling Sun,Walter Royal,Suzanne Gartner,Wuyuan Lu,Alfredo Garzino-Demo
DOI: https://doi.org/10.1097/01.qai.0000413810.48264.fc
2012-01-01
Journal of Acquired Immune Deficiency Syndromes
Abstract:CCR2 and CCR6 are the two cellular receptors known to bind, besides chemokines, human β-defensin (hBD) 2 and -3, antimicrobial peptides secreted by epithelial cells. Both receptors are of crucial relevance in HIV infection. CCR6 is expressed, often concurrently with CCR5, on cells that are highly susceptible to HIV infection: memory T cells, Th17 cells, α4β7+ cells. Decreased frequencies of CD4+CCR6+ cells have been associated with faster AIDS progression, and Th17 cells are selectively lost in HIV infection. CCR2 is expressed on monocytes and macrophages, cells that are reservoirs of HIV infection and that are known to mediate central nervous system damage. Our studies show that hBD2, hBD3, and CCR6 ligand MIP-3a/CCL20 inhibit HIV infection via CCR6 by increasing expression of the antiviral protein APOBEC3G. This increase is due to a transcriptional mechanism mediated by intracellular signaling. hBD2 also inhibits HIV replication in macrophages that express CCR2. Our findings suggest novel therapeutic and preventive approaches that exploit CCR6 and CCR2-mediated intracellular signaling to inhibit HIV infection in highly susceptible cells.
What problem does this paper attempt to address?